



This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is posted here by 
agreement between Elsevier and the University of Turin. Changes resulting from the publishing process - 
such as editing, corrections, structural formatting, and other quality control mechanisms - may not be 
reflected in this version of the text. The definitive version of the text was subsequently published in 
[Gastroenterology. 2013 May;144(5):1098-106. doi: 10.1053/j.gastro.2013.01.020].  
 
You may download, copy and otherwise use the AAM for non-commercial purposes provided that your 
license is limited by the following restrictions: 
 
(1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-ND 
license.  
(2) The integrity of the work and identification of the author, copyright owner, and publisher must be 
preserved in any copy.  
(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en), [+ Digital Object Identifier link to the 
published journal article on Elsevier’s ScienceDirect® platform]  
 2 
Vaccination	  with	  ENO1-­‐DNA	  Prolongs	  Survival	  of	  Genetically	  Engineered	  
Mice	  with	  Pancreatic	  Cancer	  
	  
PAOLA	  CAPPELLO1,2,	  SIMONA	  ROLLA1,2,	  ROBERTO	  CHIARLE1,	  MOITZA	  PRINCIPE1,2,	  FEDERICA	  CAVALLO2,3,	  
GIOVANNI	  PERCONTI4,5,	  SALVATORE	  FEO4,5,	  MIRELLA	  GIOVARELLI1,2,	  FRANCESCO	  NOVELLI1,2.	  
 
1Center	  for	  Experimental	  Research	  and	  Medical	  Studies	  (CERMS),	  Città	  della	  Salute	  e	  della	  Scienza	  di	  Torino,	  and	  
2Department	  of	  Molecular	  Biotechnology	  and	  Health	  Science,	  University	  of	  Torino,	  10125	  Torino,	  Italy;	  
3Molecular	  Biotechnology	  Center,	  University	  of	  Torino,	  10126	  Turin,	  Italy;	  4Department	  of	  Experimental	  
Oncology	  and	  Clinical	  Applications,	  University	  of	  Palermo,	  and	  5Institute	  of	  Biomedicine	  and	  Molecular	  
Immunology,	  National	  Council	  of	  Research,	  90100	  Palermo,	  Italy.	  
	  
Short	  title:	  DNA	  vaccination	  delays	  PDA	  progression	  
	  
This	  work	  was	  supported	  by	  the	  Associazione	  Italiana	  per	  la	  Ricerca	  sul	  Cancro	  (AIRC	  IG	  n.11643,	  5	  x	  1000	  
n.12182);	  Ministero	  dell’Istruzione,	  dell’Università	  e	  della	  Ricerca	  (MIUR),	  Progetti	  di	  Rilevante	  Interesse	  
Nazionale	  (PRIN);	  Ministero	  della	  Sanità:	  Progetto	  Integrato	  Oncologia;	  Regione	  Piemonte:	  Ricerca	  Industriale	  e	  
Sviluppo	  Precompetitivo	  (ONCOPROT),	  Ricerca	  Industriale	  “Converging	  Technologies”	  (BIOTHER),	  Progetti	  
strategici	  su	  tematiche	  di	  interesse	  regionale	  o	  sovra	  regionale	  (IMMONC),	  Ricerca	  Sanitaria	  Finalizzata,	  Ricerca	  
Sanitaria	  Applicata;	  European	  Community,	  European	  Community's	  Seventh	  Framework	  Programme	  (FP7/2007-­‐
 3 
2013)	  under	  Grant	  agreement	  n°256974.	  P.C.	  was	  supported	  by	  a	  fellowship	  from	  Fondazione	  Italiana	  Ricerca	  
sul	  Cancro	  (FIRC).	  
	  
Abbreviations:	  ENO1,	  alpha-­‐enolase;	  CDC,	  complement-­‐dependent	  cytotoxicity;	  GEM,	  genetically	  engineered	  
mice;	  KC,	  KrasG12D/Cre	  mice;	  KPC,	  KrasG12D/Trp53R172H/Cre	  mice;	  MDSC,	  myeloid-­‐derived	  suppressor	  cells;	  PDA,	  
pancreatic	  ductal	  adenocarcinoma;	  Treg,	  T	  regulatory	  lymphocytes	  
	  
Correspondence:	  Francesco	  Novelli,	  PhD,	  CeRMS-­‐University	  of	  Turin,	  Via	  Cherasco	  15	  10125-­‐Torino,	  Italy.	  
Phone:	  +39	  011	  6334463,	  Fax:	  +39	  011	  633	  6887,	  Email:	  franco.novelli@unito.it	  
	  
Competing	  interest	  statement:	  The	  authors	  declare	  that	  they	  have	  no	  competing	  financial	  interests.	  
	  
Authors’	  Contributions:	  PC	  designed	  experiments,	  acquired,	  analyzed	  data	  and	  wrote	  the	  paper;	  SR	  acquired	  
and	  analyzed	  data;	  RC	  analyzed	  all	  histological	  samples;	  FC	  provided	  the	  electroporator	  instrument,	  as	  well	  as	  
valuable	  scientific	  comments;	  MP	  performed	  the	  CDC	  experiments;	  GP	  and	  SF	  provided	  ENO1	  full-­‐length	  coding	  
plasmids	  and	  expertise	  in	  protein	  purification;	  MG	  helped	  to	  design	  experiments;	  FN	  supervised	  the	  study,	  




BACKGROUND	  &	  AIMS:	  Pancreatic	  ductal	  adenocarcinoma	  (PDA)	  is	  an	  aggressive	  tumor,	  and	  patients	  typically	  
present	  with	  late-­‐stage	  disease;	  rates	  of	  5-­‐year	  survival	  after	  pancreaticoduodenectomy	  are	  low.	  Antibodies	  
against	  α-­‐enolase	  (ENO1),	  a	  glycolytic	  enzyme,	  are	  detected	  in	  more	  than	  60%	  of	  patients	  with	  PDA,	  and	  ENO1-­‐
specific	  T	  cells	  inhibit	  the	  growth	  of	  human	  pancreatic	  xenograft	  tumors	  in	  mice.	  We	  investigated	  whether	  an	  
ENO1	  DNA	  vaccine	  elicits	  anti-­‐tumor	  immune	  responses	  and	  prolongs	  survival	  of	  mice	  that	  spontaneously	  
develop	  autochthonous,	  lethal	  pancreatic	  carcinomas.	  	  
	  
METHODS:	  We	  injected	  and	  electroporated	  a	  plasmid	  encoding	  ENO1	  (or	  a	  control	  plasmid)	  into	  KrasG12D/Cre	  
mice	  (KC)	  and	  KrasG12D/Trp53R172H/Cre	  (KPC)	  mice	  when	  they	  were	  4	  weeks	  old	  (when	  pancreatic	  intraepithelial	  
lesions	  are	  histologically	  evident).	  Anti-­‐tumor	  humoral	  and	  cellular	  responses	  were	  analyzed	  by	  histology,	  
immunohistochemistry,	  ELISAs,	  flow	  cytometry,	  and	  ELISpot	  and	  cytotoxicity	  assays.	  Survival	  was	  analyzed	  by	  
Kaplan-­‐Meier	  analysis.	  
	  
RESULTS:	  The	  ENO1	  vaccine	  induced	  antibody	  and	  a	  cellular	  responses	  and	  increased	  survival	  times	  by	  a	  
median	  138	  days	  in	  KC	  mice	  and	  42	  days	  in	  KPC	  mice,	  compared	  with	  mice	  given	  the	  control	  vector.	  In	  
histologic	  analysis,	  the	  vaccine	  appeared	  to	  slow	  tumor	  progression.	  The	  vaccinated	  mice	  had	  increased	  serum	  
levels	  of	  anti-­‐ENO1	  immunoglobulin	  G,	  which	  bound	  the	  surface	  of	  carcinoma	  cells	  and	  induced	  complement-­‐
dependent	  cytotoxicity.	  ENO1	  vaccination	  reduced	  numbers	  of	  myeloid-­‐derived	  suppressor	  cells	  and	  T-­‐
regulatory	  cells,	  and	  increased	  T-­‐helper	  1	  and	  17	  responses.	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CONCLUSIONS:	  In	  a	  genetic	  model	  of	  pancreatic	  carcinoma,	  vaccination	  with	  ENO1	  DNA	  elicits	  humoral	  and	  
cellular	  immune	  responses	  against	  tumors,	  delays	  tumor	  progression,	  and	  significantly	  extends	  survival.	  This	  
vaccination	  strategy	  might	  be	  developed	  as	  a	  neo-­‐adjuvant	  therapy	  for	  patients	  with	  PDA.	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Introduction	  
Pancreatic	  ductal	  adenocarcinoma	  (PDA)	  is	  the	  fourth	  leading	  cause	  of	  cancer-­‐related	  death	  in	  the	  Western	  
countries.	  Surgical	  resection	  is	  the	  only	  potentially	  curative	  treatment.	  Unfortunately,	  because	  of	  the	  late	  
presentation	  of	  the	  disease,	  only	  15-­‐20%	  of	  patients	  are	  candidates	  for	  pancreatectomy.	  However,	  the	  five-­‐
year	  survival	  following	  pancreaticoduodenectomy	  is	  only	  25-­‐30%	  for	  node-­‐negative,	  and	  10%	  for	  node-­‐positive	  
tumors	  1,	  2.	  Effective	  diagnostic	  and	  therapeutic	  strategies	  are	  still	  urgently	  needed	  to	  improve	  this	  survival	  
rate.	  We	  have	  used	  SERological	  Proteome	  Analysis	  to	  identify	  a	  dozen	  antigens	  expressed	  by	  PDA	  and	  
recognized	  by	  autoantibodies	  present	  in	  the	  sera	  of	  patients	  with	  pancreatic	  cancer,	  but	  not	  in	  sera	  of	  other	  
tumor	  patients,	  patients	  with	  pancreatitis	  or	  healthy	  donors	  3.	  One	  of	  these	  antigens,	  α-­‐enolase	  (ENO1),	  is	  
specifically	  recognized	  by	  over	  60%	  of	  PDA	  patients	  4.	  ENO1	  is	  coded	  by	  the	  ENO1	  gene,	  is	  overexpressed	  in	  the	  
cytoplasm	  of	  PDA	  cells	  and	  is	  also	  present	  on	  their	  membrane	  5.	  In	  the	  cytoplasm,	  ENO1	  acts	  as	  a	  glycolytic	  
enzyme,	  whereas	  on	  the	  membrane	  it	  acts	  as	  a	  plasminogen	  receptor	  and	  plays	  an	  important	  role	  in	  cell	  
migration	  6,	  7.	  We	  have	  shown	  that	  PDA	  patients	  with	  autoantibodies	  to	  ENO1	  also	  present	  an	  ENO1-­‐specific	  T	  
cell	  response,	  which	  is	  not	  observed	  in	  patients	  with	  no	  ENO1	  autoantibodies.	  Upon	  transferral	  into	  
immunocompromised	  mice,	  ENO1-­‐specific	  T	  cells	  inhibit	  the	  growth	  of	  xenotransplanted	  human	  pancreatic	  
tumors.	  Despite	  the	  ubiquitous	  presence	  of	  ENO1	  in	  all	  mammalian	  cells,	  normal	  cells	  expressing	  low	  levels	  of	  
ENO1,	  are	  spared	  by	  ENO1-­‐specific	  cytotoxic	  T	  lymphocytes	  5.	  
In	  this	  work,	  we	  used	  two	  GEM	  strains	  (KrasG12D/Cre	  mice,	  KC	  mice,	  and	  KrasG12D/Trp53R172H/Cre,	  KPC	  mice)	  that	  
develop	  autochthonous	  lethal	  pancreatic	  carcinomas	  with	  different	  kinetics	  8,	  9	  in	  order	  to	  study	  the	  protective	  
effect	  of	  a	  DNA	  vaccine	  to	  human	  ENO1.	  
Mice	  were	  vaccinated	  with	  plasmids	  encoding	  human	  ENO1	  as	  it	  displays	  more	  than	  95%	  identity	  (99%	  
homology)	  with	  the	  mouse	  ortholog.	  Vaccination,	  starting	  from	  4	  weeks	  of	  age,	  when	  pancreatic	  intraepithelial	  
lesions	  are	  already	  histologically	  evident	  8	  elicits	  an	  integrated	  humoral	  and	  cellular	  immune	  response	  to	  ENO1	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that	  significantly	  extends	  survival.	  Our	  data	  also	  show	  a	  new	  role	  of	  ENO1	  in	  skewing	  the	  T	  cell	  response	  
toward	  a	  Th17-­‐type	  response.	  ENO1	  vaccination	  may	  therefore	  be	  a	  promising	  neo-­‐adjuvant	  form	  of	  PDA	  
management.	  
 8 
Material	  and	  Methods	  
Mice.	  
Mice	  carrying	  single-­‐mutated	  KrasG12D	  (C57BL/6;129SvJae	  H-­‐2b)	  or	  double-­‐mutated	  (KrasG12D	  and	  Trp53R172H)	  
(129SvJae	  H-­‐2b)	  under	  the	  endogenous	  promoter	  and	  flanked	  by	  Lox-­‐STOP-­‐Lox	  cassettes	  were	  obtained	  from	  
Dr.	  David	  Tuveson	  (Cancer	  Research	  UK,	  Cambridge	  Research	  Institute,	  Cambridge,	  UK).	  C57BL/6	  mice	  
expressing	  Cre	  recombinase	  under	  a	  specific	  pancreatic	  transcriptional	  factor	  Pdx-­‐1	  (pancreatic	  duodenum	  
homeobox	  1)	  promoter	  were	  obtained	  from	  Dr.	  Andrew	  Lowy	  (University	  of	  San	  Diego,	  San	  Diego,	  CA).	  Mice	  
were	  bred	  and	  maintained	  under	  SAPF	  conditions	  at	  the	  animal	  facilities	  of	  the	  Molecular	  Biotechnology	  
Center,	  and	  treated	  in	  accordance	  with	  EU	  and	  Institutional	  guidelines.	  Pancreatic	  cancer	  -­‐prone	  KC	  and	  KPC	  
mice	  were	  generated	  by	  crossing	  single-­‐mutated	  KrasG12D	  or	  double-­‐mutated	  KrasG12D	  and	  Trp53R172H	  with	  
C57BL/6	  mice	  expressing	  Cre	  recombinase.	  Mice	  were	  screened	  by	  PCR	  using	  tail	  DNA	  amplified	  by	  specific	  
primers	  to	  the	  Lox-­‐P	  cassette	  flanking	  Kras	  and	  wild-­‐type	  Kras	  genes,	  the	  Lox-­‐P	  cassette	  flanking	  Trp53	  mutated	  
and	  wild-­‐type	  Trp53	  and	  Cre	  recombinase	  genes.	  PCR	  products	  were	  separated	  on	  1.5%	  agarose	  gels	  with	  
GelRed	  (Biotum	  by	  SIC,	  Rome,	  Italy)	  and	  recorded	  as	  .tiff.	  	  
	  
DNA	  Vaccination	  
KC	  and	  KPC	  mice	  were	  vaccinated	  at	  4	  weeks	  of	  age	  and	  every	  3	  weeks,	  for	  a	  total	  of	  three	  rounds	  of	  
vaccination,	  or	  every	  2	  weeks,	  and	  for	  a	  total	  of	  four	  rounds	  of	  vaccination.	  In	  the	  therapeutical	  DNA	  
vaccination	  setting,	  KC	  mice	  were	  vaccinated	  at	  32-­‐36	  weeks	  of	  age	  and	  every	  3	  weeks,	  for	  a	  total	  of	  three	  
rounds	  of	  vaccination.	  Injection	  of	  50	  µg	  of	  plasmid	  in	  40	  µl	  of	  sterile	  water	  with	  0.9%	  NaCl	  into	  the	  femoral	  
muscle	  of	  mice	  anesthetized	  with	  Zoletil	  e	  Xylazina	  was	  immediately	  followed	  by	  two	  25	  msec	  pulses	  of	  375	  
V/cm	  applied	  with	  a	  CLINIPORATOR™	  and	  linear	  needle	  electrodes	  (IGEA,	  Carpi,	  Italy).	  KC	  and	  KPC	  mice	  of	  the	  
same	  age	  were	  randomly	  assigned	  to	  control	  and	  treatment	  groups,	  and	  all	  groups	  were	  specifically	  treated	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concurrently.	  Mice	  were	  monitored	  weekly	  and	  left	  to	  live	  unless	  showing	  obvious	  signs	  of	  pain,	  so	  as	  to	  obtain	  
a	  Kaplan-­‐Meier	  survival	  curve.	  Parallel	  mice	  were	  sacrificed	  at	  4,	  24	  and	  36	  weeks	  of	  age	  as	  indicated,	  to	  
perform	  histological	  or	  immunohistochemical	  analyses.	  
Human	  ENO1	  cDNA	  was	  obtained	  by	  enzyme	  digestion	  of	  the	  plasmid	  pRC-­‐ENO1	  10	  (kindly	  provided	  by	  
Giallongo	  A,	  Institute	  of	  Biomedicine	  and	  Molecular	  Immunology,	  National	  Council	  of	  Research,	  Palermo,	  Italy)	  
in	  HindIII	  and	  XbaI	  restriction	  sites	  (both	  from	  M-­‐Medical,	  Milan,	  Italy),	  followed	  by	  separation	  by	  
electrophoresis	  on	  agarose	  gel	  and	  elution.	  It	  was	  then	  cloned	  into	  pVAX1	  (Invitrogen,	  Milan,	  Italy),	  previously	  
digested	  with	  the	  same	  restriction	  enzymes,	  by	  ligation.	  In	  order	  to	  propagate	  and	  maintain	  empty	  and	  pVAX-­‐
ENO1	  vectors,	  the	  competent	  recA1,	  endA	  E.	  coli	  strain	  (TOP10)	  was	  transformed	  with	  the	  empty	  pVAX	  and	  
ligation	  mixture,	  and	  selected	  on	  Luria	  Bertoni	  plates	  containing	  50	  µg/ml	  kanamycin.	  
	  
Cells	  
Syngeneic	  murine	  DT6606	  and	  K8484	  cells	  were	  kindly	  provided	  by	  Dr	  K.	  Olive	  (Li	  Ka	  Shing	  Centre,	  Cambridge	  
Research	  Institute,	  Cancer	  Research	  UK,	  Cambridge,	  UK).	  They	  were	  obtained	  from	  a	  KrasG12D/Cre	  and	  a	  
KrasG12D/Trp53R172H/Cre	  pancreatic	  tumor	  mass,	  respectively,	  and	  were	  maintained	  in	  vitro	  in	  DMEM-­‐10%	  FBS.	  
	  
ELISA.	  Anti-­‐ENO1	  IgG	  were	  measured	  by	  ELISA	  by	  binding	  to	  human	  rENO1	  (1.5	  μg/ml	  in	  Na2CO3	  0.1M),	  
produced	  as	  previously	  described	  5.	  Sera	  collected	  2	  weeks	  after	  three	  rounds	  of	  vaccination	  were	  diluted	  
1:500	  in	  PBS	  and	  antibody	  concentration	  was	  calculated	  by	  regression	  analysis	  using	  eight	  two-­‐fold	  serial	  





Sera	  from	  untreated	  and	  empty	  or	  ENO1-­‐vaccinated	  mice	  were	  used	  to	  stain	  DT6606	  or	  K8484	  cells,	  which	  
were	  analyzed	  by	  flow	  cytometry	  after	  dilution	  of	  1:50.	  Briefly,	  1	  x	  105	  cells	  were	  washed	  with	  PBS-­‐0.2%	  BSA-­‐
0.01%	  NaN3,	  and	  incubated	  with	  diluted	  sera	  for	  1h	  at	  4°C.	  After	  two	  washes,	  cells	  were	  incubated	  with	  an	  APC-­‐
conjugated	  anti-­‐mouse	  antibody	  (1:200;	  Biolegend)	  for	  30	  min	  on	  ice.	  Following	  washing,	  10,000	  cells	  were	  
acquired	  with	  a	  FACSCanto	  using	  CellQuest	  software	  (both	  BD	  Biosciences).	  The	  antibody	  titer	  is	  expressed	  as	  
sbp	  x	  10-­‐3/ml,	  calculated	  as	  previously	  described	  in	  detail11.	  
	  
Complement-­‐dependent	  cytotoxicity.	  
DT6606	  or	  K8484	  cells	  were	  seeded	  in	  a	  96-­‐well	  plate	  (5	  x	  103/well)	  in	  DMEM-­‐1%	  FBS	  overnight,	  for	  adhesion.	  
Cells	  were	  washed	  with	  warm	  PBS	  and	  incubated	  with	  sera	  diluted	  in	  PBS	  (1:50)	  for	  1h	  at	  4°C,	  washed	  again,	  
followed	  by	  incubation	  with	  fresh	  reconstituted	  rabbit	  complement	  (Low-­‐Tox	  rabbit	  complement	  from	  
Cederlane)	  diluted	  1:25	  in	  PBS	  for	  1h	  at	  37°C.	  Lysis	  was	  evaluated	  with	  the	  CytoTox	  96	  Non-­‐Radioactive	  
Cytotoxicity	  Assay	  (Promega).	  Lysis	  buffer	  was	  added	  to	  cells	  45	  min	  prior	  to	  centrifugation	  in	  order	  to	  obtain	  
the	  maximum	  release	  of	  lactate	  dehydrogenase	  (LDH),	  while	  cells	  without	  serum	  and	  complement	  were	  used	  
as	  a	  measure	  of	  spontaneous	  release	  of	  LDH.	  Plates	  were	  centrifuged	  at	  250	  x	  g	  for	  4	  minutes	  and	  50	  µL	  of	  
supernatant	  was	  transferred	  to	  the	  enzymatic	  assay	  plate	  and	  incubated	  with	  50	  µL	  of	  substrate	  Mix	  for	  30	  min	  
at	  room	  temperature	  in	  the	  dark.	  Stop	  solution	  (50µL)	  was	  added	  to	  each	  well	  and	  absorbance	  was	  recorded	  at	  
490	  nm	  with	  a	  plate	  reader.	  An	  LDH	  positive	  control	  was	  added	  in	  new	  wells	  of	  each	  plate	  and	  all	  tests	  were	  
performed	  in	  triplicate.	  The	  percentage	  of	  specific	  lysis	  was	  calculated	  using	  the	  following	  formula:	  
%	  cytotoxicity	  =	  [(Experimental-­‐Target	  spontaneous)	  /	  (Target	  maximum-­‐Target	  spontaneous)]	  x	  100	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IFN-­‐γ	  Elispot	  assay.	  
Mouse	  lymph	  node	  and	  spleen	  cells	  were	  evaluated	  to	  determine	  the	  presence	  of	  T	  cells	  able	  to	  secrete	  IFN-­‐γ	  
in	  response	  to	  rENO1	  or	  DT6606	  cells,	  ex-­‐vivo	  or	  after	  1	  week	  of	  in	  vitro	  culture	  in	  the	  presence	  of	  10μg/ml	  of	  
rENO1.	  Nitrocellulose	  plates	  (Millipore,	  Milan,	  Italy)	  were	  coated	  with	  anti-­‐IFN-­‐γ	  capture	  mAb	  (mIFN-­‐γ	  kit	  by	  
BD)	  overnight	  at	  4	  °C.	  T	  cells	  from	  lymph	  nodes	  and	  spleens	  ex-­‐vivo,	  or	  recovered	  from	  a	  1	  week	  culture	  were	  
stimulated	  with	  DT6606	  cells	  (1:10	  =	  S:E)	  or	  rENO1,	  for	  40	  h	  at	  37	  °C.	  T	  cells	  were	  seeded	  at	  3	  x	  105	  cells/well	  
and	  all	  conditions	  were	  carried	  out	  in	  quadruplicate.	  Plates	  were	  then	  developed	  as	  indicated	  by	  the	  
manufacturer	  using	  AEC	  (Sigma-­‐Aldrich)	  substrate,	  and	  spots	  were	  quantified	  with	  the	  microplated	  reader	  
along	  with	  a	  computer-­‐assisted	  image	  analysis	  system	  (AID,	  Amplifon,	  Milan,	  Italy).	  The	  number	  of	  spots	  was	  




Mouse	  MDSC	  were	  analyzed	  by	  staining	  whole	  blood	  after	  red	  cell	  lysis	  with	  0.83%	  NH4Cl-­‐0.1%	  KHCO3-­‐0.04%	  
EDTA	  buffer	  and	  washing	  with	  PBS-­‐0.2%	  BSA-­‐0.01%	  NaN3.	  This	  was	  followed,	  after	  blocking	  nonspecific	  sites,	  by	  
incubation	  with	  mAbs	  from	  Biolegend:	  anti-­‐CD16/CD32	  mAb,	  anti-­‐CD11b	  and	  anti-­‐Gr1.	  Mouse	  PBMC-­‐	  isolated	  
by	  Ficoll	  centrifugation-­‐	  were	  washed	  with	  PBS-­‐0.2%	  BSA-­‐0.01%	  NaN3,	  stained	  with	  CD4	  and	  CD25	  mAbs	  (all	  
from	  Biolegend),	  and	  subsequently	  fixed	  and	  permeabilized	  with	  Fixation	  and	  Permabilization	  solution	  
(eBiosciences)	  for	  30’	  at	  4°C.	  After	  washing	  with	  Permeabilization	  buffer,	  cells	  were	  incubated	  for	  30	  min	  with	  
FoxP3	  and	  RoRγt	  mAbs	  (both	  from	  eBiosciences).	  Spleen	  cells	  (2x106/ml)	  from	  control	  or	  ENO1-­‐vaccinated	  mice	  
were	  stimulated	  with	  PMA	  (50	  ng/ml)	  and	  Ionomycin	  (2	  μg/ml)	  in	  the	  presence	  of	  the	  intracellular	  protein	  
transport	  inhibitor	  brefeldin	  A	  (Sigma)	  ex	  vivo	  or	  after	  1	  week	  of	  culture	  in	  the	  presence	  of	  rENO1.	  Cells	  were	  
harvested	  5	  h	  later,	  labeled	  with	  a	  CD4	  mAb,	  and	  subsequently	  fixed	  with	  a	  2%	  paraformaldehyde	  solution.	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Cells	  were	  permeabilized	  using	  PBS-­‐0.2%	  BSA-­‐0.5%	  saponin	  and	  subsequently	  incubated	  for	  30	  min	  with	  mAbs	  
specific	  for	  TNF-­‐α,	  IFN-­‐γ	  and	  IL-­‐17	  (all	  from	  BD	  or	  Biolegend).	  All	  flow	  cytometry	  data	  were	  acquired	  on	  a	  
FACSCalibur	  (BD)	  and	  analyzed	  using	  FlowJo	  (Tree	  Star)	  or	  CellQuest	  Software	  (BD).	  
	  
Histology.	  
Pancreas,	  spleen,	  liver	  and	  lungs	  from	  control	  and	  ENO1-­‐vaccinated	  mice	  were	  sampled	  at	  the	  indicated	  times,	  
fixed	  in	  formalin	  and	  subsequently	  paraffin-­‐embedded.	  We	  quantified	  the	  percentage	  of	  transformed	  ducts	  
compared	  to	  normal	  ducts	  on	  histological	  sections	  from	  H&E	  sections	  of	  the	  pancreas,	  according	  to	  the	  criteria	  
previously	  established	  8.	  
For	  immunohistochemical	  analysis,	  slides	  were	  subjected	  to	  microwaving	  for	  20	  min	  in	  10	  mmol/L	  of	  citrate	  
buffer	  (pH	  8.0	  for	  nuclear	  antigens;	  pH	  6.0	  for	  other	  antigens).	  Immunostaining	  was	  performed	  using	  the	  avidin	  
biotin	  peroxidase	  complex	  method	  or	  detected	  using	  the	  Dako	  Envision	  Plus	  Rabbit	  Polymer	  (K4033)	  and	  a	  
semiautomated	  immunostainer	  (DAKO,	  Carpinteria,	  CA,	  USA	  or	  Ventana	  Systems,	  Tucson,	  AZ,	  USA).	  Primary	  
antibody	  used	  was	  a	  rat	  anti-­‐mouse	  FoxP3	  1:50	  (eBiosciences)	  and	  a	  rat	  anti-­‐mouse	  CD3	  1:100	  (Dako).	  Reactive	  
T	  lymphocytes	  and	  Treg	  cells	  were	  quantified	  by	  measuring	  the	  percentages	  of	  CD3+	  and	  FoxP3+	  cells,	  
respectively,	  among	  the	  total	  mononuclear	  cells	  infiltrating	  the	  neoplastic	  pancreatic	  glands.	  
	  
Statistical	  analysis.	  
We	  used	  an	  unpaired	  two-­‐tailed	  Student's	  t-­‐test	  for	  all	  comparisons.	  Kaplan-­‐Mayer	  survival	  curves	  were	  




The	  ENO1	  vaccine	  induces	  both	  an	  antibody	  and	  a	  cellular	  response.	  
PDA-­‐prone	  KC	  mice	  were	  electroporated	  either	  with	  empty	  plasmid	  or	  human	  ENO1-­‐encoding	  plasmid.	  The	  
amount	  of	  antibodies	  able	  to	  bind	  recombinant	  human	  ENO1	  (rENO1)	  was	  evaluated	  at	  2	  weeks	  after	  the	  last	  
electroporation.	  Anti-­‐ENO1	  antibodies	  were	  significantly	  induced	  in	  ENO1-­‐vaccinated	  KC	  mice,	  but	  not	  in	  those	  
vaccinated	  with	  the	  empty	  vector	  (Figure	  1A).	  
To	  evaluate	  the	  functional	  role	  of	  anti-­‐ENO1	  antibodies,	  we	  first	  analyzed	  the	  ability	  of	  sera	  from	  empty	  or	  
ENO1-­‐vaccinated	  mice	  to	  bind	  the	  cell	  surface	  of	  murine	  PDA	  cells	  by	  flow	  cytometry,	  by	  measuring	  their	  
binding	  potential	  (Figure	  1B-­‐D).	  Despite	  a	  weak	  cell	  decoration	  also	  being	  observed	  with	  sera	  from	  untreated	  
mice,	  those	  from	  ENO1-­‐vaccinated	  mice	  displayed	  higher	  serum	  binding	  potential	  (Figure	  1B)	  and	  a	  significantly	  
higher	  ability	  to	  mediate	  complement-­‐dependent	  killing	  of	  both	  murine	  PDA	  K8484	  and	  DT6606	  cells	  (Figure	  
1D).	  
Spleen	  and	  lymph	  node	  cells	  from	  untreated,	  empty-­‐vaccinated,	  and	  ENO1-­‐vaccinated	  mice	  were	  collected	  2	  
weeks	  after	  the	  final	  vaccination,	  and	  their	  ability	  to	  secrete	  IFN-­‐γ	  was	  assessed	  in	  an	  Elispot	  assay,	  both	  ex	  vivo	  
and	  after	  7	  days	  of	  in	  vitro	  re-­‐stimulation	  with	  the	  rENO1.	  Ex	  vivo	  splenocytes	  from	  untreated	  and	  empty-­‐
vaccinated	  control	  mice	  (white	  and	  gray	  bars)	  displayed	  few	  specific	  spots	  when	  stimulated	  with	  rENO1	  (Figure	  
2B,	  C).	  In	  contrast,	  ex	  vivo	  T	  cells	  from	  ENO1-­‐vaccinated	  mice	  (black	  bars)	  displayed	  a	  significantly	  higher	  
number	  of	  IFN-­‐γ-­‐secreting	  cells	  in	  response	  to	  rENO1	  (Figure	  2B),	  which	  increased	  three-­‐fold	  after	  the	  in	  vitro	  
rENO1	  re-­‐stimulation	  (Figure	  2D).	  When	  DT6606	  cells	  were	  used	  for	  stimulation,	  only	  rENO1	  re-­‐stimulated	  T	  
cells	  from	  ENO1-­‐vaccinated	  mice	  specifically	  secreted	  IFN-­‐γ	  (Figure	  1E).	  No	  IFN-­‐γ-­‐secreting	  cells	  appeared	  when	  
DT6606	  cells	  were	  pre-­‐incubated	  with	  an	  anti-­‐MHC	  class	  I	  antibody.	  Similar	  results	  were	  obtained	  with	  lymph	  
node	  cells	  (data	  not	  shown).	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ENO1	  DNA	  vaccine	  prolongs	  mouse	  survival.	  
As	  electroporation	  of	  human	  ENO1-­‐encoding	  plasmid	  induces	  both	  cellular	  and	  antibody-­‐mediated	  immune	  
reactions,	  the	  therapeutic	  efficacy	  of	  this	  response	  was	  evaluated.	  As	  shown	  in	  Figure	  3	  (A,	  B),	  almost	  all	  KC	  
mice	  displayed	  transformed	  foci	  in	  the	  pancreas	  at	  the	  moment	  of	  the	  first	  electroporation.	  Their	  number	  
increased	  until	  the	  tumor	  mass	  reached	  85-­‐100	  %	  of	  the	  pancreas	  and	  50%	  of	  mice	  died	  around	  336	  days	  of	  
age	  due	  to	  the	  presence	  of	  large	  tumors	  (Figure	  3C).	  The	  vaccination	  with	  empty	  vector	  slightly	  prolonged	  the	  
median	  of	  survival	  by	  56	  days	  (p=0.9,	  Log-­‐rank	  Mantel-­‐Cox	  test).	  In	  ENO1-­‐vaccinated	  mice,	  the	  median	  survival	  
is	  extended	  by	  140	  days	  (50%	  of	  mice	  died	  around	  474	  days,	  p=0.033	  vs	  untreated	  mice,	  Log-­‐rank	  Mantel-­‐Cox	  
test)	  (Figure	  3C),	  which	  amounts	  to	  more	  than	  one-­‐third	  of	  their	  life	  expectancy.	  Despite	  the	  slight	  increase	  
induced	  by	  the	  unspecific	  vaccination	  and	  electroporation,	  the	  ENO1	  vaccine	  significantly	  prolonged	  the	  
survival	  by	  a	  further	  82	  days	  (p=0.036	  vs	  empty-­‐vaccinated	  mice,	  Log-­‐rank	  Mantel-­‐Cox	  test).	  
Even	  the	  survival	  of	  the	  double-­‐mutated	  KPC	  mice,	  whose	  faster	  tumor	  progression	  is	  evident	  from	  their	  
shorter	  median	  survival	  (203	  days	  compared	  to	  336	  days	  of	  KC),	  is	  prolonged	  by	  42	  days	  (20%	  of	  life	  
expectancy;	  p=0.034	  vs	  untreated	  mice	  and	  p=0.025	  vs	  empty-­‐vaccinated	  mice,	  Log-­‐rank	  Mantel-­‐Cox	  test)	  in	  
ENO1-­‐vaccinated	  mice	  but	  not	  in	  empty-­‐vaccinated	  mice	  (50%	  of	  mice	  died	  around	  160	  days;	  p=0.25	  vs	  
untreated	  mice,	  Log-­‐rank	  Mantel-­‐Cox	  test)	  (Figure	  3D).	  
Because	  of	  the	  small	  number	  of	  available	  KPC	  mice,	  histological	  and	  immunological	  studies	  were	  conducted	  on	  
KC	  mice	  only.	  Histological	  analysis	  performed	  at	  24	  and	  36	  weeks	  of	  age	  with	  randomly	  vaccinated	  mice	  (n	  =	  5	  
per	  group)	  confirmed	  the	  ability	  of	  the	  ENO1	  vaccine,	  and	  to	  a	  lesser	  extent,	  electroporation	  with	  the	  empty	  
plasmid,	  to	  reduce	  the	  percentage	  of	  transformed	  ducts	  compared	  to	  control	  mice.	  At	  24	  weeks,	  while	  
untreated	  KC	  mice	  displayed	  58%	  of	  already	  transformed	  pancreatic	  ducts,	  those	  empty-­‐vaccinated	  or	  those	  
receiving	  ENO1	  vaccine	  displayed	  only	  18	  and	  25.5%,	  respectively	  (Figure	  3E).	  At	  36	  weeks,	  ducts	  were	  shown	  
to	  be	  transformed	  in	  85%	  of	  the	  pancreas	  of	  untreated	  mice	  and	  56%	  in	  those	  empty-­‐vaccinated,	  compared	  
with	  only	  40%	  in	  those	  ENO1-­‐vaccinated	  (Figure	  3F):	  two	  of	  these	  mice	  displayed	  an	  almost	  normal	  pancreas,	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suggesting	  a	  complete	  recovery.	  
	  
ENO1	  DNA	  vaccine	  inhibits	  Myeloid-­‐Derived	  Suppressor	  Cell	  and	  Treg	  expansion	  and	  promotes	  the	  Th17	  
response.	  
As	  myeloid-­‐derived	  suppressor	  cells	  (MSDC)	  and	  regulatory	  T	  cells	  (Treg)	  have	  been	  reported	  in	  KC	  mice	  12,	  the	  
effect	  of	  ENO1-­‐DNA	  vaccination	  on	  these	  cell	  subsets	  was	  investigated.	  Compared	  to	  control	  mice	  at	  12	  weeks	  
of	  age,	  there	  was	  a	  similar	  percentage	  of	  MSDC	  (white	  bars,	  Figure	  4A,	  left	  panel)	  in	  the	  blood	  of	  empty-­‐
vaccinated	  mice	  (gray	  bars),	  which	  significantly	  decreased	  in	  ENO1-­‐vaccinated	  mice	  (black	  bars),	  with	  an	  even	  
more	  pronounced	  effect	  in	  Treg	  cells	  (Figure	  4A	  right	  panel).	  The	  percentages	  of	  MSDC	  and	  Treg	  cells	  in	  ENO1-­‐
vaccinated	  mice	  then	  increased	  to	  those	  of	  control	  mice	  at	  52	  and	  76	  weeks	  (Figure	  4A).	  
Immunohistochemical	  examination	  of	  pancreatic	  tissues	  from	  untreated	  mice	  shows	  a	  progressive	  increase	  of	  
FoxP3+	  cells	  in	  transformed	  ducts	  from	  3%	  at	  4	  weeks	  of	  age	  to	  13%	  at	  24	  weeks	  and	  19%	  at	  36	  weeks.	  Empty-­‐
vaccination	  did	  not	  alter	  this	  progress,	  whereas	  the	  ENO1-­‐vaccine	  significantly	  diminished	  both	  the	  24-­‐	  and	  the	  
36-­‐week	  percentages	  (Figures	  4B-­‐F).	  It	  will	  be	  seen	  that	  these	  two	  percentages	  are	  stable.	  
Compared	  to	  untreated	  and	  empty-­‐vaccinated	  mice,	  in	  ENO1-­‐vaccinated	  mice	  the	  percentage	  of	  Treg	  cells	  
decreased	  in	  parallel	  with	  the	  increase	  of	  the	  percentage	  of	  cells	  expressing	  RoRγt,	  a	  transcriptional	  factor	  
related	  to	  Th17	  cells	  13	  (data	  not	  shown).	  This	  corresponded	  to	  an	  increased	  percentage	  of	  cells	  secreting	  IL-­‐17	  
and	  TNF-­‐α,	  two	  signature	  cytokines	  of	  Th17	  cells	  14,	  accompanied	  by	  an	  increase	  of	  IFN-­‐γ	  secreting	  cells	  in	  CD4+	  
spleen	  cells	  from	  ENO1-­‐vaccinated	  mice	  (Figure	  5A).	  After	  7	  days	  of	  in	  vitro	  re-­‐stimulation,	  the	  percentage	  of	  
IL-­‐17,	  TNF-­‐α,	  IFN-­‐γ	  and	  IL-­‐17/TNF-­‐α	  secreting	  cells	  significantly	  increased	  even	  further	  (Figure	  5B).	  
Furthermore,	  we	  analyzed	  by	  immunohistochemistry	  the	  CD3	  infiltrate	  into	  neoplastic	  foci	  from	  pancreas	  
collected	  from	  untreated	  mice	  and	  mice	  vaccinated	  with	  empty	  or	  ENO1-­‐expressing	  plasmids.	  As	  shown	  in	  
figure	  5	  (panels	  C-­‐F),	  the	  percentage	  of	  CD3	  on	  total	  inflammatory	  cells	  in	  the	  neoplastic	  foci	  was	  significantly	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higher	  in	  ENO1-­‐vaccinated	  mice	  compared	  to	  that	  observed	  in	  empty-­‐vaccinated	  or	  untreated	  mice.	  
These	  results	  suggest	  that	  only	  the	  ENO1-­‐vaccination	  was	  able	  to	  induce	  specific	  Th17	  cells	  in	  parallel,	  and	  to	  
diminish	  the	  frequency	  of	  suppressor	  cells	  such	  as	  MDSC	  and	  Treg	  cells,	  and	  of	  note,	  to	  actively	  recruit	  CD3	  
cells	  into	  tumor.	  
	  
Therapeutical	  ENO1	  DNA	  vaccine	  significantly	  slows	  PDA	  progression.	  
To	  evaluate	  the	  effect	  of	  ENO1	  vaccine	  in	  a	  setting	  closer	  to	  that	  applicable	  in	  patients	  lately	  diagnosed	  or	  
chemo-­‐	  and	  radio-­‐resistant,	  we	  vaccinated	  mice	  at	  32-­‐36	  weeks	  of	  age.	  Mice	  were	  sacrificed	  at	  52	  weeks	  of	  age	  
to	  evaluate	  by	  histological	  analysis	  the	  percentage	  of	  transformed	  ducts	  compared	  to	  the	  normal	  ducts.	  Empty-­‐
vaccinated	  mice	  showed	  around	  79%	  of	  transformed	  ducts	  compared	  to	  about	  50%	  observed	  in	  the	  pancreas	  
of	  ENO1-­‐vaccinated	  mice	  (Figure	  6A).	  Of	  note,	  despite	  the	  difference	  in	  the	  presence	  of	  transformed	  ducts	  is	  
not	  statistically	  different,	  the	  mean	  of	  dimension	  of	  the	  largest	  tumor	  is	  strongly	  and	  significantly	  less	  in	  ENO1-­‐
vaccinated	  mice	  compared	  to	  that	  evaluated	  in	  empty-­‐vaccinated	  mice	  (Figure	  6B).	  These	  results	  suggest	  that	  
even	  in	  a	  desperate	  attempt	  to	  tackle	  PDA	  when	  tumors	  are	  well	  established,	  ENO1	  vaccine	  seems	  to	  have	  
efficacy	  in	  delay	  tumor	  progression.	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Discussion	  
We	  have	  previously	  demonstrated	  that	  ENO1,	  a	  novel	  PDA-­‐associated	  antigen,	  could	  be	  a	  promising	  
therapeutic	  candidate	  owing	  to	  its	  ability	  to	  induce	  an	  integrated	  humoral	  and	  cellular	  response	  5.	  The	  few	  
PDA-­‐associated	  antigens	  (CEA,	  Kras,	  MUC1	  and	  gastrin)	  that	  have	  already	  been	  tested	  in	  clinical	  trials	  have	  
demonstrated	  to	  have	  no	  impact	  on	  survival	  15.	  This	  highlights	  the	  challenge	  to	  identify	  new	  and	  more	  
significant	  immunogenic	  targets.	  
Here	  we	  show,	  for	  the	  first	  time,	  that	  a	  DNA	  vaccine	  coding	  for	  a	  ubiquitous	  protein	  significantly	  induces	  a	  
specific	  immune	  response	  that	  prolongs	  survival	  in	  a	  mouse	  model	  of	  PDA.	  Despite	  ENO1	  being	  widely	  
expressed,	  we	  have	  previously	  demonstrated	  that	  normal	  cells,	  whose	  ENO1	  levels	  are	  lower	  than	  those	  of	  
tumor	  cells,	  are	  spared	  from	  antigen-­‐specific	  killing	  5.	  
In	  this	  study,	  LSL-­‐KrasG12D	  mice	  crossed	  with	  Pdx-­‐1-­‐Cre	  mice	  (KC	  mice)	  were	  used	  to	  obtain	  the	  specific	  
expression	  of	  mutated	  KrasG12D	  in	  pancreatic	  cells.	  Each	  tumor	  evolves	  from	  a	  background	  of	  genomic	  
instability	  that	  gives	  rise	  to	  a	  polyclonal	  tumor	  whose	  physiopathological	  features	  are	  similar	  to	  those	  of	  human	  
PDA	  8.	  Indeed,	  high	  resolution	  assessments	  of	  chromosomal	  content	  have	  previously	  indicated	  that	  non-­‐
reciprocal	  translocations	  were	  found	  in	  most	  neoplastic	  cells	  that	  were	  analyzed	  16.	  This,	  and	  similar	  models	  of	  
GEM,	  have	  been	  used	  to	  address	  therapeutic	  issues,	  but	  have	  never	  been	  for	  as	  long	  as	  in	  our	  study.	  We	  show	  
that	  ENO1	  DNA	  vaccination	  significantly	  prolongs	  survival	  from	  336	  to	  474	  days	  of	  age,	  the	  longest	  overall	  
survival	  ever	  reported.	  
In	  this	  study	  we	  show	  that	  the	  ENO1-­‐vaccinated	  mice	  displayed	  higher	  amount	  of	  serum	  anti-­‐ENO1	  IgG	  and	  
notably,	  that	  they	  are	  able	  to	  bind	  the	  cell	  surface	  of	  murine	  PDA	  cells	  and	  induce	  their	  killing	  by	  complement-­‐
dependent	  cytotoxicity,	  which	  has	  been	  proposed	  as	  an	  effector	  mechanism	  of	  anti-­‐tumor	  immunity	  17,	  18.	  Anti-­‐
ENO1	  antibody	  induction	  correlates	  with	  the	  increase	  of	  ENO1-­‐specific	  Th1	  and	  Th17	  T	  cells.	  The	  latter,	  in	  
particular,	  may	  be	  crucially	  important	  in	  helping	  B	  cells	  to	  produce	  a	  pronounced	  amount	  of	  antibodies	  with	  
 18 
preferential	  isotype	  class	  switching	  to	  IgG1,	  IgG2a,	  IgG2b,	  and	  IgG3	  19,	  and	  IFN-­‐γ	  to	  IgG2a	  20.	  Accordingly,	  we	  
have	  documented	  a	  strong	  increase	  of	  T	  lymphocytes	  that	  infiltrate	  tumor	  area	  in	  ENO1	  vaccinated	  mice.	  	  We	  
are	  currently	  investigating	  other	  anti-­‐tumor	  mechanisms	  dependent	  on	  anti-­‐ENO1	  IgG,	  specially	  after	  the	  
important	  demonstration	  by	  Guo	  et	  al.	  that,	  in	  addition	  to	  surface	  molecules,	  proteins	  hidden	  within	  cells	  can	  
also	  be	  attacked	  by	  antibodies	  21.	  Another	  possible	  role	  is	  the	  inhibition	  of	  migration	  of	  pancreatic	  tumor	  cells	  
or	  MDSC	  into	  the	  tumor	  through	  the	  ENO1-­‐plasminogen	  pathway	  blockade	  22,	  23.	  
An	  additional	  important	  effect	  of	  ENO1	  vaccination	  is	  the	  significant	  decrease	  of	  MDSC	  and	  Treg	  cells.	  The	  
massive	  secretion	  of	  IL-­‐6	  in	  the	  pancreas	  of	  ENO1-­‐vaccinated	  mice	  (data	  not	  shown)	  may	  explain	  the	  increase	  
of	  Th17	  rather	  than	  FoxP3+	  cells	  24.	  Th	  17	  cells	  recruit	  neutrophils	  and	  eosinophils	  25,	  also	  present	  in	  pancreatic	  
tumor	  lesions	  from	  empty-­‐vaccinated	  mice	  (data	  not	  shown),	  and	  this	  native	  immune	  response	  partly	  impeded	  
tumor	  progression,	  particularly	  at	  the	  beginning;	  indeed,	  at	  24	  weeks	  of	  age,	  both	  empty	  and	  ENO1-­‐vaccinated	  
mice	  presented	  a	  lower	  percentage	  of	  transformed	  pancreatic	  ducts	  compared	  to	  untreated	  mice.	  However,	  
only	  the	  combination	  of	  the	  innate	  and	  acquired	  immune	  responses	  induced	  by	  the	  ENO1	  vaccination	  was	  able	  
to	  significantly	  delay	  the	  tumor	  progression.	  At	  36	  weeks	  of	  age,	  only	  ENO1-­‐vaccinated	  mice	  showed	  the	  lower	  
percentage	  of	  transformed	  pancreatic	  ducts,	  and	  two	  of	  these	  five	  mice	  displayed	  an	  almost	  entirely	  
histologically-­‐normal	  pancreas.	  Nevertheless,	  when	  suppressive	  immune	  cells	  restored	  percentages	  similar	  to	  
those	  of	  the	  controls,	  progression	  was	  no	  longer	  counteracted	  and	  death	  ensued.	  It	  is	  however	  possible	  that	  
repeated	  boosters	  are	  required,	  as	  for	  other	  antigens,	  to	  maintain	  the	  minimal	  antigen	  concentration	  
necessary	  for	  the	  adequate	  effector	  activation.	  Thus,	  all	  studies	  aimed	  to	  limit	  suppressor	  cells	  by	  a	  
combination	  of	  different	  strategies	  are	  highly	  applicable,	  and	  it	  is	  likely	  that	  a	  combined	  vaccination	  schedule	  
or	  different	  settings	  might	  be	  more	  efficient.	  In	  a	  GEM	  model	  of	  lung	  adenocarcinoma,	  vaccination	  clearly	  
stimulated	  specific	  T	  cells	  which	  soon	  disappeared;	  tumor	  growth,	  in	  parallel,	  was	  slower	  at	  the	  beginning	  but	  
then	  became	  similar	  to	  that	  in	  control	  mice	  26.	  This	  also	  endorses	  the	  great	  potential	  of	  the	  vaccination	  even	  if	  
researchers	  have	  still	  to	  work	  on	  the	  most	  effective	  combination	  and	  timing.	  The	  choice	  of	  xenogenic	  rather	  
 19 
than	  syngeneic	  antigen	  or	  other	  kind	  of	  vectors	  remains	  open:	  many	  studies	  have	  demonstrated	  that	  human	  
TAA	  compared	  to	  the	  mouse	  ortholog,	  or	  viral	  vectors	  compared	  to	  plasmid	  vectors	  used	  to	  vaccinate	  tumor-­‐
bearing	  mice	  are	  more	  efficient	  in	  inducing	  tumor	  immunity	  as	  well	  as	  autoimmunity.	  Thus,	  xenogenic	  TAA	  or	  
viral	  components	  aid	  the	  immune	  system	  in	  breaking	  tolerance	  or	  ignorance	  against	  a	  “self”-­‐protein	  27-­‐
29_ENREF_27.	  In	  our	  case,	  we	  have	  previously	  demonstrated	  that	  PBMC	  from	  PDA	  patients	  specifically	  secreted	  
IFNγ	  in	  response	  to	  the	  syngeneic	  recombinant	  protein,	  and	  here	  we	  show	  that	  mice	  vaccinated	  with	  the	  
xenogenic	  protein	  produce	  antibodies	  against	  the	  syngeneic	  native	  protein.	  
Our	  results	  are	  however	  very	  promising.	  Few	  of	  the	  many	  new	  strategies	  seem	  to	  be	  effective	  in	  prolonging	  
survival	  beyond	  1	  year	  15,	  while	  the	  optimal	  adjuvant	  approach	  after	  resection	  is	  still	  unclear	  30.	  Together	  these	  
findings	  suggest	  that	  ENO1-­‐vaccination	  in	  resected	  PDA	  patients	  might	  increase	  the	  Th17	  population	  and	  limit	  
the	  expansion	  of	  the	  MDSC,	  leading	  to	  an	  effective	  immune	  response	  that	  tackles	  the	  recurrence.	  In	  addition,	  
this	  observation	  endorses	  previous	  data	  on	  the	  effector	  role	  of	  Th17	  cells	  in	  tumors	  31-­‐33	  even	  if	  their	  specific	  
contribution	  in	  PDA	  remains	  to	  be	  clarified.	  
DNA	  vaccines	  could	  be	  employed	  in	  pancreatic	  cancer	  as	  adjuvants	  to	  conventional	  treatments,	  in	  the	  
management	  of	  minimal	  residual	  disease,	  and	  as	  a	  way	  of	  increasing	  the	  overall	  survival	  of	  the	  80%	  of	  resected	  
patients	  who	  always	  develop	  recurrences.	  
Increasing	  data	  indicate	  that	  chemo-­‐immunotherapy	  may	  constitute	  a	  new	  strategy	  to	  control	  tumor	  
progression	  34.	  The	  immune	  system,	  indeed,	  could	  be	  elicited	  in	  two	  ways	  by	  conventional	  therapies.	  Some	  
therapeutic	  programs	  elicit	  specific	  cellular	  responses	  that	  render	  tumor-­‐cell	  death	  immunogenic	  35.	  Other	  
drugs	  may	  have	  side	  effects	  that	  stimulate	  the	  immune	  system	  through	  different	  mechanisms.	  Moreover,	  
vaccination	  against	  cancer-­‐specific	  antigens	  may	  sensitize	  a	  tumor	  to	  subsequent	  chemotherapy	  34,	  and	  in	  this	  
contest	  the	  ENO1	  vaccine	  can	  be	  also	  applied	  to	  chemo-­‐resistant	  PDA	  patients.	  Lastly,	  the	  chemotherapeutic	  
drug	  gemcitabine	  36,	  37	  (but	  not	  doxorubixin-­‐cyclophosphamide	  38),	  eliminates	  MDSC	  39,	  and	  cyclophosphamide	  
eliminates	  Tregs	  40,	  which	  constitute	  one	  of	  the	  main	  immunosuppressive	  factors	  in	  cancer	  as	  well	  tumor-­‐
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associated	  stromal	  cells,	  and	  several	  strategies	  targeting	  them	  are	  currently	  being	  explored	  39,	  41.	  Very	  
promising,	  indeed,	  is	  the	  therapeutical	  efficacy	  of	  ENO1	  vaccine	  observed	  when	  the	  administration	  protocol	  
started	  at	  32-­‐36	  weeks	  of	  age.	  The	  right	  drug	  combination	  might	  transform	  our	  trend	  in	  significant	  results.	  
Overall,	  present	  data	  indicate	  that	  it	  may	  be	  possible	  to	  design	  adjuvant	  therapies	  to	  elicit	  anti-­‐ENO1	  responses	  
in	  resected	  patients	  to	  prevent	  recurrences,	  or	  to	  prolong	  survival	  of	  untreatable	  patients.	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Figure	  Legends	  
Figure	  1.	  Electroporation	  of	  human	  ENO1-­‐encoding	  plasmid	  elicits	  antibodies	  to	  human	  and	  mouse	  
ENO1.	  A.	  Anti-­‐ENO1	  IgG	  was	  quantified	  by	  ELISA	  in	  sera	  from	  untreated	  (white	  bars)	  and	  empty	  (gray	  
bars)	  or	  ENO1-­‐plasmid	  (black	  bars)	  vaccinated	  mice	  after	  three	  rounds	  of	  vaccination.	  Data	  are	  
represented	  as	  mean	  ±	  SEM.	  B.	  Serum	  binding	  potential	  evaluated	  by	  flow	  cytometry	  with	  empty	  or	  
ENO1-­‐vaccinated	  mouse	  sera	  collected	  2	  weeks	  after	  the	  final	  vaccination.	  Values	  are	  expressed	  as	  mean	  
x	  10-­‐3	  ±	  SEM	  from	  8-­‐10	  mice.	  *values	  from	  ENO1-­‐vaccinated	  mice	  are	  significantly	  different	  from	  those	  of	  
empty-­‐vaccinated	  mice.	  C.	  Representative	  staining	  of	  murine	  DT6606	  PDA	  cells	  with	  sera	  from	  empty	  or	  
ENO1-­‐vaccinated	  mice	  individually	  tested.	  Open	  profiles,	  cells	  stained	  with	  secondary	  antibody	  alone;	  
solid	  black	  profiles,	  cells	  stained	  with	  sera	  from	  mice	  vaccinated	  with	  empty	  (left	  panel)	  or	  ENO1	  (right	  
panel)	  plasmids.	  Two	  representative	  stainings	  are	  shown.	  D.	  Complement-­‐dependent	  cytotoxicity	  of	  
K8484	  and	  DT6606	  cells	  with	  sera	  from	  empty	  or	  ENO1-­‐vaccinated	  mice,	  individually	  tested.	  The	  box-­‐
graphs	  include	  single	  %	  of	  lysis	  ±	  SEM,	  while	  the	  horizontal	  bars	  represent	  the	  median	  for	  each	  group	  of	  
sera.	  *	  p<	  0.05	  and	  ***	  p<	  0.0001	  values	  from	  ENO1-­‐vaccinated	  mice	  are	  significantly	  different	  from	  
those	  of	  empty-­‐vaccinated	  mice	  
Figure	  2.	  ENO1-­‐	  vaccine	  elicits	  cellular	  responses	  to	  human	  and	  mouse	  ENO1.	  Spleen	  cells	  from	  untreated	  
mice	  (white	  bars),	  empty	  plasmid	  (gray	  bars)	  or	  ENO1-­‐plasmid	  -­‐vaccinated	  (black	  bars)	  mice	  were	  
stimulated	  in	  Elispot	  plate	  with	  rENO1	  (A,	  C)	  or	  DT6606	  cells	  (B,	  D)	  ex-­‐vivo	  (A,	  B)	  or	  after	  7	  days	  of	  
stimulation	  with	  rENO1	  (C,	  D).	  DT6606	  cells	  were	  either	  pre-­‐incubated	  or	  not	  with	  anti-­‐MHC	  class	  I	  mAb	  
(D).	  T	  cells	  cultured	  with	  medium	  alone	  are	  shown	  as	  light	  gray	  bars.	  The	  numbers	  in	  the	  graph	  represent	  
the	  mean	  no.	  of	  specific	  spots	  subtracted	  from	  that	  of	  the	  background.	  All	  conditions	  were	  in	  
quadruplicate.	  One	  of	  three	  independent	  experiments	  is	  shown,	  and	  results	  are	  expressed	  as	  mean	  ±	  
SEM,	  n	  =	  2	  for	  each	  group.	  *	  P	  <	  0.05,	  ***	  P	  <	  0.0001	  values	  compared	  to	  untreated	  mice	  and	  §§	  P	  <	  0.001,	  
§§§	  P	  <	  0.0001	  values	  compared	  to	  empty-­‐vaccinated	  mice.	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Figure	  3.	  ENO1	  vaccine	  significantly	  prolongs	  the	  survival	  of	  KC	  and	  KPC	  mice.	  A,	  B.	  From	  4	  weeks	  of	  age,	  
KC	  mice	  spontaneously	  develop	  PDA	  that	  histologically	  progresses	  from	  PanIN	  to	  carcinoma	  in	  situ.	  C,	  D.	  
Kaplan-­‐Meier	  analysis	  of	  survival	  of	  untreated	  and	  vaccinated	  with	  empty	  or	  human	  ENO1	  coding	  plasmid	  
KC	  mice	  (C)	  and	  KPC	  mice	  (D)	  monitored	  until	  their	  death.	  E.	  Percentage	  of	  transformed	  ducts	  in	  KC	  mice	  
untreated	  or	  vaccinated	  with	  empty	  or	  ENO1-­‐DNA.	  **	  P	  <	  0.001	  values	  compared	  to	  untreated	  mice.	  
Figure	  4.	  ENO1-­‐vaccination	  decreases	  MDSC	  and	  FoxP3+	  cells.	  A.	  Left	  panel:	  Whole	  blood	  from	  untreated	  
(white	  bars),	  empty-­‐vaccinated	  (gray	  bars)	  and	  ENO1-­‐vaccinated	  (black	  bars)	  mice	  was	  stained	  after	  red	  
blood	  cell	  lysis	  with	  anti-­‐CD11b	  and	  anti-­‐GR1	  mAbs,	  and	  directly	  acquired	  with	  a	  FACSCalibur.	  The	  
percentage	  of	  double	  positive	  cells	  from	  individual	  mice	  is	  reported	  as	  mean	  ±	  SEM;	  n	  =	  4-­‐8	  per	  group.	  
Right	  panel:	  the	  presence	  of	  FoxP3	  transcriptional	  factor	  was	  assessed	  in	  PBMC	  from	  untreated	  (white	  
bars),	  empty-­‐vaccinated	  (gray	  bars)	  and	  ENO1-­‐vaccinated	  (black	  bars)	  mice.	  The	  percentage	  of	  positive	  
cells	  between	  total	  CD4+/CD25+	  cells	  evaluated	  in	  each	  single	  mouse	  is	  reported	  as	  mean	  ±	  SEM;	  n	  =	  4-­‐8	  
per	  group.	  B.	  Quantification	  of	  FoxP3+	  cells	  in	  transformed	  pancreatic	  ducts	  (n=5	  for	  each	  group).	  C-­‐F.	  
Pancreases	  from	  empty	  and	  ENO1-­‐vaccinated	  mice	  sacrificed	  at	  24	  (C,	  D)	  and	  36	  (E,	  F)	  weeks	  of	  age	  
respectively	  were	  stained	  with	  the	  anti-­‐FoxP3	  Ab.	  **	  P	  <	  0.01	  values	  significantly	  different	  from	  
untreated	  mice	  and	  §§	  P	  <	  0.001,	  §§§P	  <	  0.0001	  values	  significantly	  different	  from	  empty	  vaccinated	  mice.	  
Figure	  5.	  ENO1	  vaccination	  increases	  IL17	  production.	  Spleen	  cells	  from	  untreated	  (white	  bars),	  empty-­‐
vaccinated	  (gray	  bars)	  and	  ENO1-­‐vaccinated	  (black	  bars)	  mice	  were	  stimulated	  with	  PMA	  and	  Ionomycin	  
overnight	  in	  the	  presence	  of	  brefeldin	  A,	  ex	  vivo	  (A)	  and	  after	  in	  vitro	  stimulation	  with	  rENO1	  for	  7	  days	  
(B),	  then	  stained	  for	  intracellular	  cytokines.	  The	  percentage	  of	  positive	  cells	  in	  total	  CD4+	  cells	  evaluated	  
in	  each	  single	  mouse	  is	  represented	  as	  mean	  ±	  SEM;	  n	  =	  6	  per	  group.	  *	  P	  <	  0.05	  values	  significantly	  
different	  from	  untreated	  mice	  and	  §	  P	  <	  0.05	  values	  significantly	  different	  from	  empty	  vaccinated	  mice.	  
(C)	  Quantification	  of	  CD3+	  cells	  in	  transformed	  pancreatic	  ducts	  (n=6-­‐8	  for	  each	  group).	  D-­‐F.	  Pancreases	  
from	  untreated	  (D),	  empty	  (E)	  and	  ENO1-­‐vaccinated	  (F)	  mice	  sacrificed	  at	  24	  weeks	  of	  age	  respectively	  
 24 
were	  stained	  with	  the	  anti-­‐CD3	  Ab.	  *	  P	  <	  0.05	  values	  significantly	  different	  from	  untreated	  mice;	  §§	  P	  <	  
0.01	  values	  significantly	  different	  from	  empty	  vaccinated	  mice.	  
Figure	  6.	  Late	  ENO1	  vaccination	  significantly	  delays	  PDA	  progression.	  KC	  mice	  were	  vaccinated	  starting	  at	  
32	  weeks	  of	  age	  when	  pancreatic	  ductal	  adenocarcinoma	  were	  well	  established,	  every	  3	  weeks	  for	  a	  total	  
of	  three	  rounds.	  A.	  Percentage	  of	  transformed	  ducts	  in	  KC	  mice	  vaccinated	  with	  empty	  or	  ENO1-­‐DNA	  
(n=7-­‐8	  for	  each	  group).	  B.	  Quantification	  of	  the	  largest	  focus	  (mm)	  in	  the	  pancreas	  of	  mice	  vaccinated	  






1.	   Jemal	  A,	  Siegel	  R,	  Ward	  E,	  et	  al.	  Cancer	  statistics,	  2008.	  CA	  Cancer	  J	  Clin	  2008;58:71-­‐96.	  
2.	   Omura	  N,	  Goggins	  M.	  Epigenetics	  and	  epigenetic	  alterations	  in	  pancreatic	  cancer.	  Int	  J	  Clin	  Exp	  
Pathol	  2009;2:310-­‐26.	  
3.	   Tomaino	  B,	  Cappello	  P,	  Capello	  M,	  et	  al.	  Autoantibody	  signature	  in	  human	  ductal	  pancreatic	  
adenocarcinoma.	  J	  Proteome	  Res	  2007;6:4025-­‐31.	  
4.	   Tomaino	  B,	  Cappello	  P,	  Capello	  M,	  et	  al.	  Circulating	  autoantibodies	  to	  phosphorylated	  alpha-­‐
enolase	  are	  a	  hallmark	  of	  pancreatic	  cancer.	  J	  Proteome	  Res.	  
5.	   Cappello	  P,	  Tomaino	  B,	  Chiarle	  R,	  et	  al.	  An	  integrated	  humoral	  and	  cellular	  response	  is	  elicited	  in	  
pancreatic	  cancer	  by	  alpha-­‐enolase,	  a	  novel	  pancreatic	  ductal	  adenocarcinoma-­‐associated	  
antigen.	  Int	  J	  Cancer	  2009;125:639-­‐48.	  
6.	   Capello	  M,	  Ferri-­‐Borgogno	  S,	  Cappello	  P,	  et	  al.	  alpha-­‐enolase:	  a	  promising	  therapeutic	  and	  
diagnostic	  tumor	  target.	  Febs	  J;278:1064-­‐74.	  
7.	   Pancholi	  V.	  Multifunctional	  alpha-­‐enolase:	  its	  role	  in	  diseases.	  Cell	  Mol	  Life	  Sci	  2001;58:902-­‐20.	  
8.	   Hingorani	  SR,	  Petricoin	  EF,	  Maitra	  A,	  et	  al.	  Preinvasive	  and	  invasive	  ductal	  pancreatic	  cancer	  and	  
its	  early	  detection	  in	  the	  mouse.	  Cancer	  Cell	  2003;4:437-­‐50.	  
9.	   Hruban	  RH,	  Adsay	  NV,	  Albores-­‐Saavedra	  J,	  et	  al.	  Pathology	  of	  genetically	  engineered	  mouse	  
models	  of	  pancreatic	  exocrine	  cancer:	  consensus	  report	  and	  recommendations.	  Cancer	  Res	  
2006;66:95-­‐106.	  
10.	   Giallongo	  A,	  Feo	  S,	  Moore	  R,	  et	  al.	  Molecular	  cloning	  and	  nucleotide	  sequence	  of	  a	  full-­‐length	  
cDNA	  for	  human	  alpha	  enolase.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  1986;83:6741-­‐5.	  
11.	   Giovarelli	  M,	  Cappello	  P,	  Forni	  G,	  et	  al.	  Tumor	  rejection	  and	  immune	  memory	  elicited	  by	  locally	  
released	  LEC	  chemokine	  are	  associated	  with	  an	  impressive	  recruitment	  of	  APCs,	  lymphocytes,	  
and	  granulocytes.	  J	  Immunol	  2000;164:3200-­‐6.	  
12.	   Clark	  CE,	  Hingorani	  SR,	  Mick	  R,	  et	  al.	  Dynamics	  of	  the	  immune	  reaction	  to	  pancreatic	  cancer	  from	  
inception	  to	  invasion.	  Cancer	  Res	  2007;67:9518-­‐27.	  
13.	   Martinez	  GJ,	  Nurieva	  RI,	  Yang	  XO,	  et	  al.	  Regulation	  and	  function	  of	  proinflammatory	  TH17	  cells.	  
Ann	  N	  Y	  Acad	  Sci	  2008;1143:188-­‐211.	  
14.	   Kryczek	  I,	  Banerjee	  M,	  Cheng	  P,	  et	  al.	  Phenotype,	  distribution,	  generation,	  and	  functional	  and	  
clinical	  relevance	  of	  Th17	  cells	  in	  the	  human	  tumor	  environments.	  Blood	  2009;114:1141-­‐9.	  
 26 
15.	   Laheru	  D,	  Jaffee	  EM.	  Immunotherapy	  for	  pancreatic	  cancer	  -­‐	  science	  driving	  clinical	  progress.	  Nat	  
Rev	  Cancer	  2005;5:459-­‐67.	  
16.	   Hingorani	  SR,	  Wang	  L,	  Multani	  AS,	  et	  al.	  Trp53R172H	  and	  KrasG12D	  cooperate	  to	  promote	  
chromosomal	  instability	  and	  widely	  metastatic	  pancreatic	  ductal	  adenocarcinoma	  in	  mice.	  Cancer	  
Cell	  2005;7:469-­‐83.	  
17.	   Weiner	  LM,	  Murray	  JC,	  Shuptrine	  CW.	  Antibody-­‐based	  immunotherapy	  of	  cancer.	  Cell	  
2012;148:1081-­‐4.	  
18.	   Shuptrine	  CW,	  Surana	  R,	  Weiner	  LM.	  Monoclonal	  antibodies	  for	  the	  treatment	  of	  cancer.	  Semin	  
Cancer	  Biol	  2012;22:3-­‐13.	  
19.	   Mitsdoerffer	  M,	  Lee	  Y,	  Jager	  A,	  et	  al.	  Proinflammatory	  T	  helper	  type	  17	  cells	  are	  effective	  B-­‐cell	  
helpers.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A;107:14292-­‐7.	  
20.	   Hasbold	  J,	  Hong	  JS,	  Kehry	  MR,	  et	  al.	  Integrating	  signals	  from	  IFN-­‐gamma	  and	  IL-­‐4	  by	  B	  cells:	  
positive	  and	  negative	  effects	  on	  CD40	  ligand-­‐induced	  proliferation,	  survival,	  and	  division-­‐linked	  
isotype	  switching	  to	  IgG1,	  IgE,	  and	  IgG2a.	  J	  Immunol	  1999;163:4175-­‐81.	  
21.	   Guo	  K,	  Li	  J,	  Tang	  JP,	  et	  al.	  Targeting	  intracellular	  oncoproteins	  with	  antibody	  therapy	  or	  
vaccination.	  Sci	  Transl	  Med;3:99ra85.	  
22.	   Lopez-­‐Alemany	  R,	  Longstaff	  C,	  Hawley	  S,	  et	  al.	  Inhibition	  of	  cell	  surface	  mediated	  plasminogen	  
activation	  by	  a	  monoclonal	  antibody	  against	  alpha-­‐Enolase.	  Am	  J	  Hematol	  2003;72:234-­‐42.	  
23.	   Wygrecka	  M,	  Marsh	  LM,	  Morty	  RE,	  et	  al.	  Enolase-­‐1	  promotes	  plasminogen-­‐mediated	  recruitment	  
of	  monocytes	  to	  the	  acutely	  inflamed	  lung.	  Blood	  2009;113:5588-­‐98.	  
24.	   Gnerlich	  JL,	  Mitchem	  JB,	  Weir	  JS,	  et	  al.	  Induction	  of	  Th17	  cells	  in	  the	  tumor	  microenvironment	  
improves	  survival	  in	  a	  murine	  model	  of	  pancreatic	  cancer.	  J	  Immunol;185:4063-­‐71.	  
25.	   Fujita	  K,	  Ewing	  CM,	  Sokoll	  LJ,	  et	  al.	  Cytokine	  profiling	  of	  prostatic	  fluid	  from	  cancerous	  prostate	  
glands	  identifies	  cytokines	  associated	  with	  extent	  of	  tumor	  and	  inflammation.	  Prostate	  
2008;68:872-­‐82.	  
26.	   DuPage	  M,	  Cheung	  AF,	  Mazumdar	  C,	  et	  al.	  Endogenous	  T	  cell	  responses	  to	  antigens	  expressed	  in	  
lung	  adenocarcinomas	  delay	  malignant	  tumor	  progression.	  Cancer	  Cell;19:72-­‐85.	  
27.	   Weber	  LW,	  Bowne	  WB,	  Wolchok	  JD,	  et	  al.	  Tumor	  immunity	  and	  autoimmunity	  induced	  by	  
immunization	  with	  homologous	  DNA.	  J	  Clin	  Invest	  1998;102:1258-­‐64.	  
28.	   Bowne	  WB,	  Srinivasan	  R,	  Wolchok	  JD,	  et	  al.	  Coupling	  and	  uncoupling	  of	  tumor	  immunity	  and	  
autoimmunity.	  J	  Exp	  Med	  1999;190:1717-­‐22.	  
29.	   Overwijk	  WW,	  Tsung	  A,	  Irvine	  KR,	  et	  al.	  gp100/pmel	  17	  is	  a	  murine	  tumor	  rejection	  antigen:	  
induction	  of	  "self"-­‐reactive,	  tumoricidal	  T	  cells	  using	  high-­‐affinity,	  altered	  peptide	  ligand.	  J	  Exp	  
Med	  1998;188:277-­‐86.	  
 27 
30.	   Li	  J,	  Merl	  MY,	  Chabot	  J,	  et	  al.	  Updates	  of	  adjuvant	  therapy	  in	  pancreatic	  cancer:	  where	  are	  we	  
and	  where	  are	  we	  going?	  Highlights	  from	  the	  "2010	  ASCO	  Annual	  Meeting".	  Chicago,	  IL,	  USA.	  
June	  4-­‐8,	  2010.	  Jop;11:310-­‐2.	  
31.	   Kryczek	  I,	  Wei	  S,	  Szeliga	  W,	  et	  al.	  Endogenous	  IL-­‐17	  contributes	  to	  reduced	  tumor	  growth	  and	  
metastasis.	  Blood	  2009;114:357-­‐9.	  
32.	   Martin-­‐Orozco	  N,	  Muranski	  P,	  Chung	  Y,	  et	  al.	  T	  helper	  17	  cells	  promote	  cytotoxic	  T	  cell	  activation	  
in	  tumor	  immunity.	  Immunity	  2009;31:787-­‐98.	  
33.	   Zou	  W,	  Restifo	  NP.	  T(H)17	  cells	  in	  tumour	  immunity	  and	  immunotherapy.	  Nat	  Rev	  
Immunol;10:248-­‐56.	  
34.	   Zitvogel	  L,	  Apetoh	  L,	  Ghiringhelli	  F,	  et	  al.	  Immunological	  aspects	  of	  cancer	  chemotherapy.	  Nat	  Rev	  
Immunol	  2008;8:59-­‐73.	  
35.	   Kroemer	  G,	  Zitvogel	  L.	  Death,	  danger,	  and	  immunity:	  an	  infernal	  trio.	  Immunol	  Rev	  2007;220:5-­‐7.	  
36.	   Suzuki	  E,	  Kapoor	  V,	  Jassar	  AS,	  et	  al.	  Gemcitabine	  selectively	  eliminates	  splenic	  Gr-­‐1+/CD11b+	  
myeloid	  suppressor	  cells	  in	  tumor-­‐bearing	  animals	  and	  enhances	  antitumor	  immune	  activity.	  Clin	  
Cancer	  Res	  2005;11:6713-­‐21.	  
37.	   Ko	  HJ,	  Kim	  YJ,	  Kim	  YS,	  et	  al.	  A	  combination	  of	  chemoimmunotherapies	  can	  efficiently	  break	  self-­‐
tolerance	  and	  induce	  antitumor	  immunity	  in	  a	  tolerogenic	  murine	  tumor	  model.	  Cancer	  Res	  
2007;67:7477-­‐86.	  
38.	   Diaz-­‐Montero	  CM,	  Salem	  ML,	  Nishimura	  MI,	  et	  al.	  Increased	  circulating	  myeloid-­‐derived	  
suppressor	  cells	  correlate	  with	  clinical	  cancer	  stage,	  metastatic	  tumor	  burden,	  and	  doxorubicin-­‐
cyclophosphamide	  chemotherapy.	  Cancer	  Immunol	  Immunother	  2009;58:49-­‐59.	  
39.	   Gabrilovich	  DI,	  Nagaraj	  S.	  Myeloid-­‐derived	  suppressor	  cells	  as	  regulators	  of	  the	  immune	  system.	  
Nat	  Rev	  Immunol	  2009;9:162-­‐74.	  
40.	   Sistigu	  A,	  Viaud	  S,	  Chaput	  N,	  et	  al.	  Immunomodulatory	  effects	  of	  cyclophosphamide	  and	  
implementations	  for	  vaccine	  design.	  Semin	  Immunopathol;33:369-­‐83.	  
41.	   Kraman	  M,	  Bambrough	  PJ,	  Arnold	  JN,	  et	  al.	  Suppression	  of	  antitumor	  immunity	  by	  stromal	  cells	  
expressing	  fibroblast	  activation	  protein-­‐alpha.	  Science;330:827-­‐30.	  
	  
	  
	  
 28 
Figure	  1	  
	  
	  
 29 
Figure	  2	  
	  
	  
 30 
Figure	  3	  
	  
	  
 31 
Figure	  4	  
	  
 32 
Figure	  5	  
	  
	  
 33 
Figure	  6	  
	  
	  
